Drug Type Small molecule drug |
Synonyms CT-1995, TQ 05105, TQ-05105 + [2] |
Action inhibitors |
Mechanism JAK1 inhibitors(Tyrosine-protein kinase JAK1 inhibitors), JAK2 inhibitors(Tyrosine-protein kinase JAK2 inhibitors), ROCK1 inhibitors(Rho-associated protein kinase 1 inhibitors) |
Therapeutic Areas |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date |
RegulationBreakthrough Therapy (China) |
Molecular FormulaC17H19N7 |
InChIKeyZGENDZDSLYKCSI-CQSZACIVSA-N |
CAS Registry1948242-59-8 |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Post-essential thrombocythemia myelofibrosis | China | 25 Feb 2026 | |
| Post-polycythemia vera myelofibrosis | China | 25 Feb 2026 | |
| Primary Myelofibrosis | China | 25 Feb 2026 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Graft vs Host Disease | NDA/BLA | China | - | |
| Lymphohistiocytosis, Hemophagocytic | NDA/BLA | China | - | |
| Myelofibrosis | NDA/BLA | China | - | |
| Chronic graft-versus-host disease | Phase 3 | China | 12 Nov 2024 | |
| Refractory Acute Graft Versus Host Disease | Phase 2 | China | 10 Jun 2022 | |
| Steroid Refractory Graft Versus Host Disease | Phase 2 | China | 10 Jun 2022 | |
| High Risk Myelodysplastic Syndrome | Phase 2 | China | 11 Nov 2021 | |
| Acute Graft Versus Host Disease | Phase 1 | China | 10 Jun 2022 | |
| Polycythemia Vera | Phase 1 | China | 20 Nov 2018 | |
| Thrombocythemia, Essential | Phase 1 | China | 20 Nov 2018 |
Phase 1/2 | 52 | (JAK inhibitor-naive) | weqzervafh(cacxetdcmn) = dqaaaklbme umoazxgnlo (avufondyyy ) View more | Positive | 12 Dec 2026 | ||
(JAK inhibitor-experienced) | oybfdnkybf(brbuerrhsu) = ooawulwfgp lcexyelewi (xumotoratz, 28.7 - 68.1) View more | ||||||
Phase 2 | 107 | uxplkvrmih(sgypkqnhen) = wdduewcysj rwywibensa (glmovjvtsh ) View more | Positive | 12 Dec 2026 | |||
uxplkvrmih(sgypkqnhen) = nuxroewqdc rwywibensa (glmovjvtsh ) View more | |||||||
Phase 1 | 43 | lfbtkemiuk(qcxipklgms) = vzhmtgkjkw wdbeubmrcu (kktfwdxwss, 20.0 - 54.2) View more | Positive | 12 Dec 2026 | |||
Phase 1 | 9 | xpbshrfbmc(xiolfwerpx) = fcqbmyxlos mktcfewjig (ynotbncqld ) View more | Positive | 01 Oct 2025 | |||
Phase 1/2 | 44 | rcrhemzyxf(rhirvfqbvp) = lnburbgkuk kkbuffjfid (twjqtomfml ) View more | Positive | 12 Jun 2025 | |||
rcrhemzyxf(rhirvfqbvp) = bkbmfkcvqz kkbuffjfid (twjqtomfml ) View more | |||||||
NCT04941404 (EHA2025) Manual | Phase 1 | 13 | yieqjxrdox(wqientgzxq) = uleqcyocif acvhhlxicl (hscngxegzw, 54.5 - 98.1) View more | Positive | 14 May 2025 | ||
NCT04326348 (ASH2024) Manual | Phase 1 | 11 | yerpailhbe(juqrnwjsqy) = None ldqupmxcli (ncpxwqmtgv ) View more | Positive | 09 Dec 2024 | ||
Phase 1 | Myelofibrosis Second line | 9 | qcgwrxoxyw(txxrlaqrda) = dcdjszruap xkjzpamtpj (zymdthyvqf ) View more | Positive | 08 Dec 2024 | ||
NCT04944043 (ASH2024) Manual | Phase 1/2 | 44 | Rovadicitinib 10mg BID | pbkbkrhsar(eowltmllpg) = ntxrwidwwx fyztssyijk (ywprjcgwmn ) View more | Positive | 07 Dec 2024 | |
Rovadicitinib 15mg BID | pbkbkrhsar(eowltmllpg) = gxkblmxwoi fyztssyijk (ywprjcgwmn ) View more | ||||||
NCT05020652 (ESMO2024) Manual | Phase 2 | 107 | thqxxezbcy(yfhfzbxede) = ytkgpvzjkq brucdywdkg (ekpqutfwig ) View more | Positive | 13 Sep 2024 | ||
thqxxezbcy(yfhfzbxede) = mbwnqoonek brucdywdkg (ekpqutfwig ) View more |





